Latent Tuberculosis Screening in Non-U.S.-Born Residents

The interferon gamma release assay is a preferred strategy for latent tuberculosis infection screening in HIV-negative, non-U.S.-born residents.

Most tuberculosis cases in the U.S. occur among immigrants, and screening for latent tuberculosis infection (LTBI) is recommended. To examine the benefits among subgroups with medical comorbidities, researchers modelled outcomes and cost-effectiveness associated with LTBI testing strategies among non-U.S.-born residents.

Non-U.S.-born residents were divided into four populations: no comorbidities, diabetes, HIV, and end-stage renal disease (ESRD). Five testing strategies were modelled: no testing, tuberculin skin test (TST), interferon gamma release assay (IGRA), confirm positive (positive TST confirmed with IGRA), and confirm negative (negative IGRA confirmed with TST). LTBI was treated with 3 months of rifapentine and isoniazid.

Testing for…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Latent Tuberculosis Screening in Non-U.S.-Born Residents

Topics

Reviewing Author